source
- AbbVie’s eczema antibody shows statistically significant benefit in Phase 2 trialAbbVie presented Phase 2 results for its experimental eczema treatment, an anti‑IL‑13 antibody named Zumilokibart. The study met its primary endpoints, demonstrating statistically significant impr…
- Massachusetts offers $40M in tax incentives to spur 1,600+ life-science jobsMassachusetts announced $40 million in tax incentives for 38 life‑science companies, targeting the creation of about 1,644 new jobs. Most of the companies-31 of them-will expand outside Boston and…